@article{article_1069557, title={DOES INTRAHEPATIC CHOLESTASIS OF PREGNANCY CAUSE A DIFFERENCE IN FETAL CARDIAC OUTPUT?}, journal={Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi}, volume={19}, pages={1159–1163}, year={2022}, DOI={10.38136/jgon.1069557}, url={https://izlik.org/JA98DD75HK}, author={Turgut, Ezgi and Denizli, Ramazan and Farisoğulları, Nihat and Sakcak, Bedri and Göncü Ayhan, Şule and Sahin, Dilek}, keywords={Fetal kalp debisi, gebeliğin intrahepatik kolestazı, serum safra asidi}, abstract={Aim: We aim to evaluate fetal cardiac output in intrahepatic cholestasis of pregnancy (ICP). Material and Method: Thirty-two patients with ICP and 42 healthy pregnant women were included in the study. The diagnosis of ICP was made by detecting fasting bile acid value >10 µmol/L in symptomatic pregnant women. Fetal echocardiographic evaluations were performed >34 weeks of gestation. Demographic data, fetal cardiac output, and perinatal outcomes of the patients were compared between the groups. Results: In the ICP group aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were higher than the control group (p <0.001 and p <0.001). The left cardiac output (LCO), right cardiac output (RCO) and combine cardiac output (CCO) were similar between the groups (p=0.430, p=0.054, and p=0.134 respectively). Patients with ICP were divided into two groups as patients with serum bile acid (SBA) >40 µmol/L, severe disease, and others mild disease. Although right, left, and combined cardiac output was decreased in the severe disease of the ICP group, there was no statistically significant difference (p=0.666, p=0.188, and p=0.236 respectively). Conclusion: In our study, we did not observe any adverse effect of ICP on fetal cardiac output, but more studies with severe ICP should be conducted.}, number={1}